Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
After finishing at $11.06 in the prior trading day, Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) closed at $11.42, up 3.25%. In other words, the price has increased by $3.25 from its previous closing price. On the day, 0.51 million shares were traded. ZNTL stock price reached its highest trading level at $11.42 during the session, while it also had its lowest trading level at $10.89.
Ratios:
Our goal is to gain a better understanding of ZNTL by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.16 and its Current Ratio is at 7.16. In the meantime, Its Debt-to-Equity ratio is 0.10 whereas as Long-Term Debt/Eq ratio is at 0.10.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Wedbush on November 08, 2023, Downgraded its rating to Neutral and sets its target price to $12 from $38 previously.
On November 07, 2023, Leerink Partners Downgraded its rating to Market Perform which previously was Outperform but kept the price unchanged to $15.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 12 ’24 when Epperly Melissa B, sold 2,573 shares for $11.44 per share. The transaction valued at 29,435 led to the insider holds 451,449 shares of the business.
Gallagher Cam sold 1,173 shares of ZNTL for $13,419 on Feb 12 ’24. The President now owns 643,277 shares after completing the transaction at $11.44 per share. On Feb 02 ’24, another insider, Gallagher Cam, who serves as the President of the company, sold 11,552 shares for $11.54 each. As a result, the insider received 133,310 and left with 644,450 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ZNTL now has a Market Capitalization of 810365504 and an Enterprise Value of 373326080.
Stock Price History:
The Beta on a monthly basis for ZNTL is 1.81, which has changed by -0.46132076 over the last 52 weeks, in comparison to a change of 0.24191546 over the same period for the S&P500. Over the past 52 weeks, ZNTL has reached a high of $31.46, while it has fallen to a 52-week low of $9.56. The 50-Day Moving Average of the stock is -18.54%, while the 200-Day Moving Average is calculated to be -33.53%.
Shares Statistics:
The stock has traded on average 829.53K shares per day over the past 3-months and 664050 shares per day over the last 10 days, according to various share statistics. A total of 70.77M shares are outstanding, with a floating share count of 63.80M. Insiders hold about 10.10% of the company’s shares, while institutions hold 110.03% stake in the company. Shares short for ZNTL as of 1713139200 were 16637859 with a Short Ratio of 20.06, compared to 1710460800 on 16735039. Therefore, it implies a Short% of Shares Outstanding of 16637859 and a Short% of Float of 31.89.
Earnings Estimates
The performance of Zentalis Pharmaceuticals Inc (ZNTL) in the stock market is under the watchful eye of 10.0 analysts actively contributing to its current rating.On average, analysts expect EPS of -$0.77 for the current quarter, with a high estimate of -$0.39 and a low estimate of -$0.96, while EPS last year was -$1.07. The consensus estimate for the next quarter is -$0.94, with high estimates of -$0.9 and low estimates of -$0.99.
Analysts are recommending an EPS of between -$3.02 and -$4.06 for the fiscal current year, implying an average EPS of -$3.66. EPS for the following year is -$3.77, with 10.0 analysts recommending between -$3.04 and -$4.45.
